immunotherapy
Kushandisa Immunotherapy Kurapa Late-Stage Cancers
Nhanganyaya Immunotherapy yave nzira inokatyamadza mukurapwa kwegomarara, kunyanya kurapwa kwegomarara repamusoro iro rakaratidza kushanda kushoma nemishonga yakajairwa. Iyi innovative appr..
Tumor-Infiltrating Lymphocyte (TIL) Therapy muChina
Feb 2024: Tumor-infiltrating lymphocyte (TIL) therapy treatment is a potential method that utilizes the body's immune system to fight solid tumors. This therapeutic area in China is advancing rapidly because of the nation's incr..
Kurapa Kwemahara Kenza muChina Pasina Kuputsa Bhangi: Gwaro Kune Vaya Vanonyanyorida
Kurapwa kwegomarara kwemahara muChina kuri kupa tariro uye kuporesa kune vanhu vanoshaya. Saka, kana iwe usingakwanise kusarudza kurapwa kenza nekuda kwemutengo wakakura, gwara iri rakagadzirirwa iwe. Ziva kuti ane mukurumbira sei organiz..
Basa reImmunotherapy Mukurapa Lymphoma
Kana iwe uri kuverenga izvi, iwe kana pamwe mumwe wevadiwa vako ari parwendo rwusina anomboronga kutora-nzira yekutarisana negomarara. Isu tinonzwisisa kuti mugwagwa uyu uzere nekusagadzikana, kutya, uye nguva dzaunonzwa ..
TIL immunotherapy, TILs kurapwa, Tumor Infiltrating Lymphocytes
Tumor Infiltrating lymphocytes (TIL) Immunotherapy muIndia
Kubvumbi 2023: Kushandisa immune system yemuviri kurwisa cancer maseru ndicho chinangwa cheanovimbisa nzira yekurapa cancer inozivikanwa se tumor infiltrating lymphocytes (TIL) immunotherapy. Maitiro aya anosanganisira kutora immune masero anonzi TI.
American Society yeHematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Inopa Yazvino Clinical Dhata paCarteyva® muFollicular Lymphoma uye Mantle Cell Lymphoma paMusangano Wepagore wechi64 ASH.
SHANGHAI, CHINA, Zvita 12, 2022 Kambani yakazvimirira uye yekugadzira biotechnology inonzi JW Therapeutics (HKEX: 2126) inotarisa mukugadzira, kugadzira, uye kutengesa zvigadzirwa zvema cell immunotherapy. Pa64th American Society ..
Cell kurapwa, China, JW Therapeutics, Shanghai
JW Therapeutics Inozivisa Kuti Cell Yayo Immunotherapy Mishonga Yakabudirira Kubatsira Varwere mazana matatu.
SHANGHAI, CHINA, Mbudzi 9, 2022 - JW Therapeutics (HKEX: 2126), yakazvimiririra uye inovandudza biotechnology kambani inotarisa mukugadzira, kugadzira, uye kushambadzira cell immunotherapy zvigadzirwa, yakazivisa kuti kubva kuN.
2makumi manomwe ehupenyu, China, immunotherapy, JW Therapeutics, ushamwari
JW Therapeutics uye 2seventy bio Inozivisa Strategic Kudyidzana Kuti Ikurumidze Tsvagiridzo uye Kukudziridzwa kweT-cell-based Immunotherapies.
SHANGHAI, CHINA neCAMBRIDGE, MASSACHUSETTS, US, Gumiguru 27, 2022 - JW Therapeutics (HKEX: 2126), yakazvimiririra uye inovandudza biotechnology kambani inotarisana nekusimudzira, kugadzira, uye kushambadzira cell immunotherap.
KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Ventana Medical Systems
Pembrolizumab inobvumidzwa kune advanced endometrial carcinoma
Kubvumbi 2022: Pembrolizumab (Keytruda, Merck) yakatenderwa neFood and Drug Administration sechinhu chimwe chete chevarwere vane advanced endometrial carcinoma iri microsatellite instability-high (MSI-H) kana mismatch repair de.
PD-1 inhibitor immunotherapy yeB B cell lymphoma
Ongororo yakanyorwa nevechidiki, MD, Anderson Cancer Center, USA yakatsanangura mashandisiro ePD-1 inhibitor immunotherapy muB-cell lymphoma. (Ropa. Vhezheni yepamhepo muna Mbudzi 8, 2017. doi: 10.1182 / blood-2017-07-740993.) PD-1 immune ..